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SUMMARY
Background
Age at presentation with primary biliary cholangitis (PBC) is associated with differ-
ential response to ursodeoxycholic acid (UDCA) therapy. Younger-presenting
patients are less likely to respond to treatment and more likely to need transplant
or die from the disease. PBC has a complex impact on quality of life (QoL), with
systemic symptoms often having signiﬁcant impact.
Aim
To explain the impact of age at presentation on perceived QoL and the inter-
related symptoms which impact upon it.
Methods
Using the UK-PBC cohort, symptoms were assessed using the PBC-40 and other
validated tools. Data were available on 2055 patients.
Results
Of the 1990 patients reporting a global PBC-QoL score, 66% reported good/neutral
scores and 34% reported poor scores. Each 10-year increase in age at presentation
was associated with a 14% decrease in risk of poor perceived QoL (OR = 0.86,
95% CI: 0.75–0.98, P < 0.05). All symptom domains were similarly age-associated
(P < 0.01). Social dysfunction was the symptom factor with the greatest impact on
QoL. Median (interquartile range) PBC-40 social scores for patients with good per-
ceived QoL were 18 (14–23) compared with 34 (29–39) for those with poor QoL.
Conclusion
The majority of patients with primary biliary cholangitis do not feel their QoL is
impaired, although impairment is reported by a sizeable minority. Age at presenta-
tion is associated with impact on perceived QoL and the symptoms impairing it,
with younger patients being more affected. Social dysfunction makes the greatest
contribution to QoL impairment, and it should be targeted in trials aimed at
improving life quality.
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INTRODUCTION
Primary biliary cholangitis [formerly known as primary
biliary cirrhosis (PBC)] is an autoimmune chronic liver
disease affecting approximately 18 000 patients in the
UK.1, 2 The condition impacts on patients through pro-
gression to end-stage liver disease with the development
of the complications of cirrhosis and the need for liver
transplantation.3 PBC patients also experience symptoms
which can have an often signiﬁcant impact on quality of
life.4, 5 These symptoms include cholestatic pruritus and
fatigue, the latter appearing to have a particular impact
on life quality.6–9
Therapy with the hydrophilic bile acid ursodeoxy-
cholic acid (UDCA) is effective in the majority of
patients; slowing disease progression and reducing risk
of death and need for transplantation.10 Second-line
therapies are now emerging for the treatment of patients
with inadequate response to UDCA.11, 12 It is becoming
increasingly clear, however, that neither UDCA nor the
emerging second-line therapies for PBC are effective at
treating symptoms. With the exception of anti-pruritic
agents, no therapies have yet been proven to improve
patients’ quality of life. This potentially leads to a ‘ther-
apy gap’ between disease prognosis, which improves with
therapy, and life quality which does not.12 The current
lack of effective therapy for systemic symptoms in PBC
highlights the need for further research into the aetiology
of symptoms and the development of novel therapies.12
Before we can effectively target quality of life impair-
ment, however, it is essential that we understand the
symptom factors that most impact on it, and develop
plausible goals for therapy applicable in clinical trials
and future practice.
Studies utilising the unique UK-PBC national patient
cohort, the largest prospective PBC cohort in the
world,13, 14 have demonstrated that age is an important
factor in the clinical expression of PBC in terms of dis-
ease severity, with patients presenting at younger ages
being less likely to respond to UDCA.15 Furthermore,
early studies using the cohort suggested that fatigue was
worse in younger than older presenting patients suggest-
ing that this group might represent one with speciﬁc
unmet need.7 This gives rise to questions as to the
impact of other symptoms in younger PBC patients and
their contribution to quality of life impairment. In this
study, we set out to use the UK-PBC patient cohort data
set to comprehensively explore the impact of symptoms
on quality of life in younger patients and to model the
complex relationships between age at presentation and
reported symptoms. The goal is to identify drivers for
poor perceived quality of life in younger patients, to
characterise potentially modiﬁable symptoms which are
under-treated and could have impact in terms of
improving quality of life and to begin to explore targets
for effective therapy which will be essential for future
treatment development.
MATERIALS AND METHODS
Patients and data collection
This study represents a further analysis of the UK-PBC
patient cohort dataset and builds on previous analy-
ses.5, 7 Data were extracted from the UK-PBC database
based on patients enrolled into the cohort between 2008
and 2011. Approach to cohort development and data
capture have been outlined previously.5, 7, 13, 14 Patients
with ‘overlap syndromes’ are excluded from UK-PBC.
Quality of life and symptom data were collected during
follow-up using the patient-completed PBC-40 assess-
ment tool,16 a median of 7 years after initial presentation
with the condition. The PBC-40 consists of 40 items in
six independently validated domains relating to fatigue,
emotional, social, cognitive function, general symptoms
and itch. Each item is scored from 1 to 5, with higher
scores denoting greater symptom severity. Other assess-
ment tools completed were the Epworth Sleepiness Scale
(ESS), Orthostatic Grading Scale (OGS) to assess auto-
nomic dysfunction, Hospital Anxiety and Depression
Scale (HADS)5; all of which have been successfully used
in PBC previously and in which, again, higher scores
denote worse symptoms. Participants were also asked to
complete a global PBC-related quality of life assessment;
a question which asks patients how much they agree
with the statement “PBC has affected my quality of life”
(1: Strongly Disagree, 2: Disagree, 3: Neither Agree nor
Disagree, 4: Agree, 5: Strongly Agree).
Liver biochemistry data were recorded for all patients
and patients who had received UDCA treatment for a
minimum of 1 year were assessed for biochemical
response using the Paris 1 clinical response criteria (re-
sponse is deﬁned as bilirubin <19 the upper limit or
normal (ULN), alanine transaminase (ALT) <29 ULN
and alkaline phosphatase (AP) <39 ULN after a mini-
mum of 1 year of UDCA therapy).17
Statistical analyses
Descriptive statistics are presented as frequencies, n (%),
and continuous covariates are presented as medians
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(interquartile range), due to underlying distributional
assumptions. Dependent variables are analysed as (i)
continuous symptom domain scores using linear regres-
sion modelling; (ii) global quality of life based on mod-
elling poor (4 or 5) compared with better quality of life
(1–3) using logistic regression modelling with 1 repre-
senting poor quality of life and 0 representing better
quality of life; (iii) global quality of life based on mod-
elling ﬁve categories of quality of life using ordinal
regression. The ratio of risks of poor quality of life
across levels of covariates is reported as an odds ratio
(OR), where an odds ratio <1 indicates a reduced risk of
poor quality of life.
Univariate regression models were developed for each
covariate investigating nonlinear relationships using Frac-
tional Polynomial Transformations.18 The best ﬁtting
model was selected based on the reduction in Akaike
Information Criterion (AIC). Multivariable models were
developed based on either full models of all covariates, or
selecting variables for inclusion based on forward selec-
tion techniques. Forward selection models select factors
which are independently explaining additional variability
and hence signiﬁcantly related to outcome. Where a for-
ward selection method was used, covariates were included
according to a 5% signiﬁcance level. Continuous covari-
ates are considered in the multivariable analysis accord-
ing to their best ﬁtting transformation. All multivariable
models include adjustment for gender and albumin ratio
(as an indicator of severity of liver disease), UDCA
response and approximate disease duration (years), mod-
elled based on a complete case dataset. UDCA response
was characterised using the ‘Paris 1’ criteria (nonresponse
being deﬁned as any of ALT ratio >2 (ratio of the value
reported to the ULN for the laboratory carrying out the
measurement), AP ratio >3 or bilirubin ratio >1). Patients
on UDCA for less than 1 year were excluded as were
those with missing data. R2 and pseudo R2 (Nagelkerke
R2) have been reported for linear regression models and
logistic regression models, respectively. Multi-collinearity
was measured using a variance inﬂation factor (VIF).
Maximum likelihood factor analysis with a Varimax
(orthogonal) rotation was conducted on the 10 quality of
life domains. The aim was to investigate natural group-
ings of correlated domains and subsequently obtain inter-
pretable loadings (weight) of each quality of life measure
within a factor. The number of factors selected was based
on eigenvalues and selected factors were used in a multi-
variable analysis.
ROC curves were calculated to explore suitable clini-
cally relevant cut-offs for patients under the age of
50 years of age for each quality of life domain below which
patients are predicted to have a poor quality of life. The
cut-off was chosen to balance sensitivity and speciﬁcity.
RESULTS
The source data for this analysis were the UK-PBC
cohort symptoms dataset which has been described pre-
viously. This is a UK-wide comprehensive cohort of PBC
patients with detailed symptom and quality of life
data.5,7 Clinical data sets were available for a total of
2055 nontransplanted patients (although the UK-PBC
cohort includes transplanted patients these were excluded
from this analysis) from 220 hospitals across the UK
(Table 1). As previously reported, the majority (91%) of
patients in the UK-PBC cohort are female, with median
age at presentation of 55 years (IQR 48–63) and median
age at study entry of 65 years (IQR 57–72). The majority
of patients (79%) were receiving UDCA therapy, how-
ever, 241 (14.8%) were excluded due to being on therapy
<1 year and 231 (14.1%) patients were unable to have a
UDCA response calculated because of missing data.
None of the patients had had a liver transplant but nine
were active on the transplant waiting list.
Age as a predictor of global perceived quality of life
A total of 1990 patients with a recorded age at presenta-
tion reported a global PBC-quality of life score. Of these,
1312 (66%) patients reported good or neutral PBC-
related quality of life scores1–3 and 678 (34%) patients
reported poor4, 5 quality of life scores; agreeing or
strongly agreeing with the statement that PBC had
impaired their quality of life (Table 1). Thus, although
the majority of PBC patients do not feel their quality of
life is impaired there is impairment seen in a sizeable
minority. We did not set out, in the study protocol
adopted, to assess non-PBC related quality of life percep-
tion. A 10-unit (10-year) increase in age at presentation
was associated with a 14% decreased risk of poor quality
of life (OR = 0.86, 95% CI: 0.75–0.98, P < 0.05), after
adjustment by gender, disease severity, UDCA response
and disease duration (Table 2a and Figure 1). Using
ordinal regression analysis, an increase in age at presen-
tation is associated with an increase in the probability of
being in the best quality of life group (‘1’) and a decrease
in the probability of being in the worst quality of life
group (‘5’) [Table 2b and Figure 2].
Age as a predictor of individual symptom severity
There were minimal missing data for the patient
reported symptom scores; PBC-40, HADS anxiety,
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HADS depression, ESS sleep and OGS autonomic scales.
Symptom severity was strongly associated with age at
presentation for all symptoms (Table 3). The relationship
between symptom severity and age at presentation was
linear for all the PBC-40 domains except itch (which
was best explained with a ﬁrst-degree fractional polyno-
mial [age0.5]). The association between age at presenta-
tion and sleep and autonomic scores were both best
explained with the same second-degree fractional poly-
nomial [age3 + age3log (age)]. For all domains and
symptom scores, increasing age at presentation is associ-
ated with decreased PBC-40 domain score. However, the
amount of variability explained in each is low
(R2 < 0.063) indicating that the variability in each
domain cannot be explained by age alone.
Symptom predictors of global quality of life
In keeping with previous analyses, the global quality of
life score was found to be strongly associated with all
symptom severity scores on univariate analysis
Table 1 | Patient Characteristics at Study Entry. Note that all percentages are out of 2055 (the total number of
patients) to show the levels of missing data apart from the two variables highlighted with a * which are out of 1629
(the number of people on UDCA)
Factor
Number of nonmissing
data points in cohort of
N = 2055 patients n (% of N) Median IQR Range
Gender (female) 2051 1858 (90.6) – – –
Age at presentation (years) 1747 55 48–63 16–86
Age at study entry (years) 2053 65 57–72 21–91
Disease duration (years) 1747 7 4–12 0–37
Not awaiting liver transplant 2055 2046 (99.6) – – –
On UDCA therapy 2055 1629 (79.3) – – –
UDCA therapy length*
<1 year 1448 241 (16.6) – – –
1–5 years 578 (39.9)
5–10 years 308 (21.3)
≥10 years 321 (22.2)
Response to treatment*
UDCA Responder 1629 892 (54.8) – – –
UDCA Nonresponder 265 (16.3)
Excluded (on UDCA<1 year) 241 (14.8)
Unknown 231 (14.1)
PBC-40 itch 1896 4 0–9 0–17
PBC-40 symptoms 2022 16 12–20 5–33
PBC-40 fatigue 2036 31 21–38 11–55
PBC-40 cognitive 2011 12 6–18 6–30
PBC-40 emotional 2007 7 5–11 3–15
PBC-40 social 2025 23 16–31 10–50
ESS sleep 2045 7 4–11 0–24
OGS autonomic 2029 3 0–5 0–18
HADS anxiety 2044 7 3–10 0–21
HADS depression 2042 4 2–7 0–21
Global QoL (ordered) 1990 3 1–4 1–5
Global QoL (binary)
Better 1990 1312 (65.9) 2 1–3 1–3
Poor 678 (34.1) 4 4–4.8 4–5
Global Health (ordered) 2021 3 3–4 1–5
Actual ALT level 1990 37 26–57 7–712
ALT ratio 1934 0.9 0.6–1.4 0.1–20.3
Actual ALP level 2018 183 126–322 33–2678
ALP ratio 1985 1.3 1.0–2.1 0.1–23.3
Actual Albumin 1887 41 38–44 18–80
Albumin ratio 1835 1.2 1.1–1.3 0.5–2.4
Actual Bilirubin 2004 9 7–13 2–168
Bilirubin ratio 1947 0.5 0.4–0.7 0.1–9.9
1042 Aliment Pharmacol Ther 2016; 44: 1039–1050
ª 2016 The Authors. Alimentary Pharmacology & Therapeutics Published by John Wiley & Sons Ltd.
J. K. Dyson et al.
(Table S1). The relationship between global quality of life
score and symptom severity was linear for each of the
PBC-40 domains. In contrast, sleep and depression were
both best explained by second-degree fractional polyno-
mials. Estimates for all individual symptom domain
scores with global quality of life score were positive indi-
cating, unsurprisingly, that an increased score results in
an increased risk of a poor quality of life. For example, a
1-unit increase in HADS anxiety score was associated
with a 21% increased risk of a poor quality of life
(OR = 1.21, 95% CI: 1.18–1.24). A forward selection
model, based on a total of 1006 patients with 360 (36%)
reporting poor quality of life showed that following
adjustment for the effects of age at presentation, as well
as gender, albumin level (as a marker for advanced dis-
ease), disease duration, and UDCA response, identiﬁed
the symptom domains of social, fatigue, anxiety and
depression as important predictors of poor perceived
quality of life (in descending order) [Table 4]. The single
most important predictor of poor quality of life is social
functioning with a 27% increased risk of being in the
Table 2 | Age at presentation and (a) overall relationship with overall perceived quality of life (good/poor)* and (b)
relationship with quality of life ordered from 1 (‘best’) to 5 (‘worst’). In each case model estimates are adjusted for
gender, albumin ratio, UDCA response and disease duration†
(a)
Outcome Covariate b^ (S.E.) OR (CI) Z value P value Pseudo R2
Good vs. Poor Quality of life Age at presentation
(10 unit increase)
0.16 (0.07) 0.86 (0.75–0.98) 2.30 0.02 0.03
Male 0.04 (0.23) 0.97 (0.61–1.51) 0.15 0.88
Albumin ratio 0.56 (0.38) 0.57 (0.27–1.20) 1.46 0.15
UDCA responder 0.28 (0.16) 0.76 (0.56–1.04) 1.75 0.08
Disease duration 0.02 (0.01) 1.02 (1.00–1.05) 1.97 0.05
(b)
b^i (S.E.) OR (CI) t value P value Pseudo R
2
Age at presentation (10 units) 0.16 (0.06) 0.85 (0.76, 0.96) 2.75 0.006 0.04
Male 0.25 (0.20) 0.78 (0.53, 1.15) 1.24 0.21
Albumin ratio 0.79 (0.32) 0.45 (0.24, 0.85) 2.48 0.01
UDCA responder 0.36 (0.14) 0.70 (0.53, 0.91) 2.65 0.008
Disease duration 0.02 (0.01) 1.02 (1.00, 1.04) 1.82 0.07
State 1–2 3.17 (0.52) 6.06 P < 0.001
State 2–3 2.19 (0.52) 4.22 P < 0.001
State 3–4 1.32 (0.52) 2.56 0.01
State 4–5 0.40 (0.52) 0.77 0.44
* In this analysis quality of life outcome is modelled on 1015 patients; 654 reporting good and 361 reporting poor quality of life.
† In this analysis quality of life outcome is modelled on 1015 patients; 233 patients reporting 1 (best quality of life), 211 patients
reporting 2, 210 patients reporting 3, 267 patients reporting 4 and 94 patients reporting 5 (worst). Ordinal regression allows the
ordinal nature of the global quality of life outcome (scored 1 ‘best’ to 5 ‘worst’) to be retained. The underlying assumption of pro-
portional odds was conﬁrmed graphically and conﬁrming no signiﬁcant difference in the likelihood ratio test comparing a propor-
tional odds model to a multinomial-logit (nonproportional odds) model. This analysis conﬁrms the increasing probability of
‘better’ global quality of life impairment scores with increasing age at presentation and conﬁrms a 10-unit increase in age at pre-
sentation to be associated with a 15% reduction in risk of poorer quality of life (OR = 0.85, 95% CI: 0.76–0.96, P < 0.01).
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Figure 1 | Predicted probability (blue line) with 95% CI
(red shade) of poor perceived quality of life with
increasing age at presentation.
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‘poor’ quality of life group with a unit increase in social
functioning score (OR = 1.27, 95% CI 1.22–1.33). Note
that, the domains are correlated so this model suffers
from multi-collinearity. This may explain why the coefﬁ-
cient for anxiety is negative which contradicts the ﬁnd-
ings in Table S1.
To investigate and group correlated symptom scores,
and address multi-collinearity, a maximum likelihood
factor analysis was performed based on a single factor as
suggested by the eigenvalues (Table S2a). A single factor
explained 54% of the total variability dominated by
social, fatigue, depression, and emotional domains. The
analysis was repeated based on two factors to investigate
robustness of the conclusions. A two factor analysis
explains 57% of total variability in the quality of life
domains, of which the ﬁrst factor explains 29% of this
variability (Table S2b). The same four domains (social,
fatigue, depression and emotional), as well as anxiety,
dominate the analysis as emotional, depression, social
and anxiety dominate the ﬁrst factor and fatigue domi-
nates the second factor. Including the second factor
explains only 3% more variability, conﬁrming the single
factor analysis to be more appropriate. The relationship
between the quality of life domains and overall quality of
life can be explored using the factor in Table S2a and ﬁt-
ting a logistic regression model adjusted for gender,
albumin, UDCA response, disease duration and age at
presentation (Table S3).
The median values for the symptom severity scores
for the good and poor quality of life group across the
whole cohort are given in Table 5a. Given the symptom
burden, and impact of quality of life impairment on the
younger-presenting patient we set out to identify cut-off
values for the symptom domains in the 493 patients in
the cohort who presented under 50 years of age that
could be explored as targets for therapy interventions in
the future (Table 5b and Figure 3). Unsurprisingly, social
dysfunction symptoms were most predictive of poor life
quality in younger patients with an area under the curve
of 91.8 (89.4–94.2) and an optimal cut-off of less than
26.5 indicating poor quality of life for the PBC-40 social
domain.
DISCUSSION
The UK-PBC patient cohort is the largest fully charac-
terised PBC patient cohort in the world. Using this data-
set, we have previously demonstrated that age of onset
of PBC is associated with speciﬁc disease characteristics,
with patients presenting at younger ages having a signiﬁ-
cantly lower likelihood of responding to therapy with
UDCA.5, 7 Our earlier analysis also suggested a potential
association between age at presentation and severity of
two of the individual symptoms of PBC, namely fatigue
and pruritus. This raises important questions relating to
the broader phenotype of disease in younger patients
and their treatment needs. The inter-relationships of
symptom sets, and their linked impacts on perceived
quality of life mean that a more integrated approach to
modelling symptom sets is appropriate and this is the
approach undertaken in the novel analysis presented
here. The unique UK-PBC data set allows us to begin to
understand the complex impact of symptoms on life
quality in younger patients. This will allow us to set
benchmark values for key symptom severity if we are to
improve quality of life, and inform future studies to
identify the key targets for therapeutic intervention.
In this study, we have demonstrated that both overall
perception of PBC-related quality of life (we did not set
out to assess non-PBC-related quality of life), and the
severity of all individual symptoms, is, as is the case with
UDCA response, strongly related to the age of onset of
disease, with younger presenting patients experiencing
the greatest impact. Importantly, this remains the case
after correcting for disease duration, UDCA response
and disease severity. Taken together, therefore, current
evidence cumulatively shows that younger-presenting
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Figure 2 | Probability of global quality of life scores
with increasing age at presentation. The global quality
of life is based on a question which asks patients how
much patients agree with the statement “PBC has
affected my quality of life” (1 or 2 represents
disagreeing with the statement (strongly or weakly), 3:
Neither Agreeing nor Disagreeing, 4 or 5 represents
agreeing (weakly or strongly). The younger patients are
at presentation the more likely they are to describe
poor quality of life (4 or 5), the older they are the
more likely they are to describe good quality of life (1
or 2).
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Table 3 | Age at presentation (‘Age’) and relationship with each quality of life domain adjusted for gender, albumin
ratio, UDCA response and disease duration
b^i (S.E.) t value P value R
2
PBC-40 itch
Age0.5 (10 unit increase) 16.13 (3.09) 5.21 <0.001 0.06
Male 0.95 (0.50) 1.91 0.06
Albumin ratio 1.06 (0.81) 1.31 0.19
UDCA response 1.10 (0.35) 3.16 <0.01
Duration 0.01 (0.03) 0.40 0.69
PBC-40 symptoms
Age (10 unit increase) 0.78 (0.17) 4.63 <0.001 0.06
Male 2.88 (0.58) 4.98 <0.001
Albumin ratio 1.56 (0.95) 1.65 0.10
UDCA response 0.36 (0.41) 0.88 0.38
Duration 0.06 (0.03) 1.82 0.07
PBC-40 fatigue
Age (10 unit increase) 1.49 (0.34) 4.34 <0.001 0.05
Male 4.30 (1.17) 3.67 <0.001
(Albumin ratio)2 5.92 (1.59) 3.71 <0.001
UDCA response 0.03 (0.83) 0.03 0.97
Duration 0.04 (0.06) 0.65 0.52
PBC-40 cognitive
Age (10 unit increase) 0.71 (0.20) 3.61 <0.001 0.02
Male 1.03 (0.68) 1.51 0.13
Albumin ratio 1.65 (1.10) 1.50 0.13
UDCA response 0.46 (0.48) 0.95 0.34
Duration 0.01 (0.04) 0.30 0.76
PBC-40 emotional
Age (10 unit increase) 0.66 (0.11) 6.16 <0.001 0.06
Male 0.96 (0.37) 2.62 <0.01
Albumin ratio 1.92 (0.60) 3.21 <0.01
UDCA response 0.01 (0.26) 0.02 0.98
Duration 0.02 (0.02) 1.20 0.23
PBC-40 social
Age (10 unit increase) 1.24 (0.30) 4.17 <0.001 0.04
Male 1.42 (1.02) 1.40 0.16
(Albumin ratio)2 4.48 (1.39) 3.23 <0.01
UDCA response 1.13 (0.72) 1.57 0.12
Duration 0.07 (0.05) 1.40 0.16
ESS sleep
Age3 (10 unit increase) 0.10 (0.03) 4.89 <0.001 0.03
Age3log(age) (10 unit increase) 0.04 (0.01)
Male 0.38 (0.54) 0.72 0.47
Albumin ratio 0.74 (0.87) 0.85 0.39
UDCA response 0.58 (0.38) 1.53 0.13
Duration 0.03 (0.03) 1.16 0.25
OGS autonomic
Age3 (10 unit increase) 0.05 (0.02) 3.05 <0.01 0.02
Age3log(age) (10 unit increase) 0.03 (0.01)
Male 0.94 (0.36) 2.63 <0.01
Albumin ratio 0.34 (0.58) 0.58 0.56
UDCA response 0.16 (0.25) 0.62 0.53
Duration 0.02 (0.02) 1.09 0.28
HADS anxiety
Age (10 unit increase) 0.64 (0.14) 4.59 <0.001 0.04
Male 1.94 (0.48) 4.06 <0.001
Albumin ratio 0.27 (0.78) 0.35 0.72
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patients are less likely to respond to therapy, are more
likely to need liver transplantation at some point in their
disease course and have more severe symptoms. We also
demonstrate a hierarchy in terms of the impact of indi-
vidual symptoms on overall perceived life quality, with
the greatest impact coming from symptoms of social iso-
lation; a ﬁnding which opens up new opportunities for
treatment targeting for quality of life improvement in
PBC.
We have previously reported, and others have con-
ﬁrmed, that the likelihood of response to UDCA therapy
in PBC is age-related, with patients presenting at
younger ages being less likely to respond.7 Taken
together with the current observation of greater symp-
tom impact and quality of life impairment in younger
patients, this raises the possibility that the biology and/or
natural history of PBC may differ between different
patient groups, with younger-presenting patients having
a more aggressive or materially different form of the dis-
ease. While our ﬁndings may reﬂect ascertainment bias
(diagnosis of PBC in younger patients, a group not typi-
cally thought of as being at risk of PBC, being more
likely in symptomatic patients who undergo clinical
assessment for their symptoms), the impact of these
symptoms on life quality is real for patients. The overall
perception of PBC-related quality of life impairment is
also strongly linked to age at presentation, with younger
patients perceiving the greatest impact on life quality.
This ﬁnding further challenges the view that PBC is a
relatively benign condition of typically older people with
limited clinical impact, and emphasises the need to
speciﬁcally consider and address the complex disease
impact in younger patients. Although we do not hold
data on comorbidity and inter-current drug therapy
numbers, both these parameters characteristically
increase with increasing patient age, suggesting that they
are unlikely to be confounders in an analysis which
shows increased symptom load at younger ages. This
study did not include a comparator disease group as
there are no comparable comprehensive liver disease
patient cohorts. However, work in inﬂammatory bowel
disease (IBD) found that diminished IBD-quality of life
was predicted by younger age and social interaction vari-
ables were associated with IBD-quality of life.19 In
Table 3 | (Continued)
b^i (S.E.) t value P value R
2
UDCA response 0.31 (0.34) 0.92 0.36
Duration 0.03 (0.02) 1.05 0.29
HADS depression
Age (10 unit increase) 0.39 (0.12) 3.32 <0.001 0.03
Male 0.37 (0.40) 0.90 0.37
(Albumin ratio)2 1.78 (0.55) 3.23 <0.01
UDCA response 0.37 (0.29) 1.30 0.19
Duration 0.01 (0.02) 0.47 0.64
Table 4 | Multivariable analysis of symptom scores adjusted by age at presentation, gender, albumin ratio, UDCA
response and disease duration as predictors of global quality of life
b^i (S.E.) OR (CI) z value P value VIF Pseudo R
2
PBC-40 social 0.24 (0.02) 1.27 (1.22–1.33) 11.05 <0.001 1.38 0.69
PBC-40 fatigue 0.07 (0.02) 1.07 (1.03–1.10) 4.03 <0.001 1.29
HADS anxiety 0.08 (0.03) 0.92 (0.87–0.98) 2.75 <0.01 1.43
HADS depression (depression + 1)0.5 2.49 (1.27) 0.08 (0.01–0.95) 1.96 0.05 1.47
HADS depression (depression + 1)3 2.19 9 106 (2.01 9 10)4 1.00 (1.00–1.00) 0.01 0.99
Male 0.53 (0.40) 1.70 (0.77–3.74) 1.33 0.18 1.09
Duration 0.02 (0.02) 1.02 (0.99–1.06) 1.27 0.20 1.11
UDCA Response 0.26 (0.25) 0.77 (0.47,1.26) 1.04 0.30 1.08
Albumin ratio 0.12 (0.61) 1.13 (0.34–3.68) 0.20 0.84 1.47
Age at presentation 0.003 (0.11) 1.00 (0.81–1.24) 0.03 0.98 1.18
Quality of life outcome is modelled on 1006 patients; 646 reporting good and 360 reporting poor quality of life.
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contrast, fatigue associated with renal transplantation has
a greater symptomatic impact in older patients.20
The relationship between symptoms and impact on
quality of life is complex, with personality and coping
skills acting as important modifying factors in individual
patients. These additional elements in the conversion of
a speciﬁc symptom into the expression of quality of life
impairment may also go some way to explaining why
symptom impact is seemingly different in different pop-
ulations with fatigue, for example, being less of an issue
in some populations than in the UK patient group. The
advent of very large data sets, such as in UK-PBC, allow
us to smooth out these individual aspects and begin to
look for over-arching trends (including, now, the impact
of age). Although understanding life quality requires a
complex approach (exploring complex aspects in an
individual way; the rationale behind the development of
the domain-based PBC-40 quality of life measure), tak-
ing an over-arching view of patient perception is also
valuable and allows us to gauge the perception of
patients as to their summary health status. Ultimately,
patient perception is critical for effective management as
the inter-relationship between this and the individual
underpinning symptoms allows identiﬁcation of the
symptoms with the greatest impact on perception of life
quality. These symptoms can then be prioritised for
clinical intervention. One important potential explana-
tion for enhanced symptom impact in younger patients
may be age-related differences in expectation of likeli-
hood of chronic disease, personal coping skills and sup-
port networks. In simple terms, younger PBC patients
(and those with other chronic diseases showing the
same symptom impact pattern) are less prepared for
chronic disease (it is not within their reasonable expec-
tation as to what might happen to them), and cope less
well, are less likely to have relevant support networks
(peer group will also be young people typically without
chronic disease) and the expectation of normal life (and
thus the gap between expectation and reality will be
greater). Further work is needed to explore these issues.
Understanding the complex psychosocial factors under-
pinning age-related quality of life impairment will be
essential, if we are to support patients better as it is
unlikely that purely pharmaceutical approaches will be
effective for such a complex problem.
Our most striking ﬁnding is that the symptom domain
with the greatest impact on perceived quality of life was
the PBC-40 social domain; a domain focused around
symptoms linked to social isolation. The greatest impact
is again seen in younger patients. This may be as a con-
sequence of the perceived ‘loss’ associated with the dis-
ease; limiting the opportunities to have a normal age-
Table 5 | Symptom scores by good/poor quality of life (a) Summary statistics across the whole cohort for the
symptom domain scores in PBC patients with good and poor quality of life. (b) ROC analysis in the 493 patients in
the cohort presenting under the age of 50
(a)
Good quality of life Poor quality of life
Median IQR Range Median IQR Range
PBC-40 social 18 14–23 10–41 34 29–39 15–50
PBC-40 fatigue 26 16–32 11–55 40 34–45 11–55
HADS anxiety 5 3–8 0–20 9 6–12 0–21
HADS depression 3 1–5 0–13 8 5–11 1–21
PBC-40 emotional 6 4–8 3–15 11 8–13 3–15
PBC-40 cognitive 9.5 6–14 6–30 18 14–21 6–30
PBC-40 itch 3 0–7 0–17 8 4–11 0–15
PBC-40 symptoms 14 10–18 5–32 19 16–23 6–33
OGS autonomic 1 0–4 0–18 5 2–7 0–18
ESS sleep 6 3–9 0–24 10 6–14 0–24
(b)
Cut-off Speciﬁcity Sensitivity AUC (95% CI)
PBC-40 social 26.5 83.9 87.1 91.8 (89.4–94.2)
PBC-40 fatigue 34.5 75.2 81.5 85.8 (82.5–89.2)
HADS anxiety 7.5 63.2 69.7 71.5 (67.0–76.1)
HADS depression 3.5 63.4 90.0 84.4 (81.0–87.8)
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appropriate social life. This ﬁnding gives rise to impor-
tant questions and therapeutic opportunities. Social func-
tioning is a modiﬁable symptom and this research
suggests that addressing and treating this single aspect
could improve global quality of life signiﬁcantly. Anecdo-
tal reports from patients give insight into the reasons for
social isolation; ranging from fatigue limiting capacity21
and desire to undertake social activity, to self-conscious-
ness relating to itching secondary to pruritus.22 Reports
of coping strategies adopted by fatigued patients often
highlight reducing work and other perceived energy-sav-
ing approaches. While offering the potential for short-
term gain in terms of fatigue, such approaches clearly
have the potential to further narrow social networks,
exacerbating social isolation and potentially worsening
quality of life. The opportunity related to our ﬁnding is
to develop novel approaches to support social structures
for symptomatic patients with the potential for a non-
pharmaceutical improvement in quality of life. Such
approaches could range from simple counselling to alert
patients to the potential for social isolation,23 to the
development of support groups (PBC research and sup-
port groups may have an important role to play), to the
development of newer digital approaches to social net-
working through social media (which may be of
particular value to younger patients). We have used
ROC analysis to identify optimal cut-offs for the symp-
toms that predict impaired quality of life in our cohort.
The value of these as targets to be achieved in therapeu-
tic intervention studies should be explored.
The other key factors associated with poor perceived
quality of life in younger patients are fatigue, anxiety
and depression. The association with fatigue is unsur-
prising given previous study ﬁndings and the identiﬁca-
tion in patient surveys of fatigue as the biggest extant
symptom problem in PBC. The impact of fatigue on life
quality means that identiﬁcation of the causes of fatigue
and approaches to its treatment should be research pri-
orities. Care should be taken, however, in managing fati-
gue to balance the potentially conﬂicting issues of fatigue
and social isolation. The individual associations of fati-
gue and depression with poor PBC-quality of life would
further suggest that fatigue in PBC is not caused by
depression. Depression and anxiety are important factors
in patient experience and should be explored in patients
with poor PBC-quality of life. These aspects may be
related to fear of the future and ability to cope, uncer-
tainty as to disease prognosis and frustration at limita-
tions to life quality. It is striking that in contrast to the
symptom domains, advanced liver disease (assessed
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Figure 3 | ROC curves of (a)
PBC-40 social domain, (b)
PBC-40 fatigue domain, (c)
HADS anxiety, (d) HADS
depression, to predict poor
quality of life in the 493
patients presenting under the
age of 50. The symptoms
analysed are those that are
predictive of poor perceived
quality of life (Table 4).
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through the surrogate marker of serum albumin) does
not associate with perceived PBC-quality of life. This is
likely to reﬂect the fact that the majority of patients with
PBC do not have advanced disease at any one time, and
that the symptom sets that do impact on quality of life
are not severity-associated.
This study sheds new light on the complex issues
underpinning the poor quality of life reported by younger
PBC patients. Our ﬁndings emphasise the complexity of
the factors linked to poor quality of life and suggest that a
holistic approach to them is essential. While speciﬁcally
targeting fatigue is likely to pay dividends, there are cur-
rently no therapies able to do that. In contrast, a more
sociological approach targeting social isolation and the
depression and anxiety which may accompany it are very
viable approaches. The beneﬁts of developing coping
strategies informed by our understanding of the impact of
social isolation should be actively explored.
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